GlassScriptPhysician profile
Joginder Pal
NPI 1194701805
$3,519.44
in general payments reported to CMS, 2019-2025
24 companies · $33.07 in 2025
The $33.07 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $982 · 2020: $363 · 2021: $938 · 2022: $736 · 2023: $330 · 2024: $136 · 2025: $33.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $499.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,013.35 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $683.02 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $433.36 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $292.20 | 2019-2024 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $138.27 | 2020-2023 | |
| Alkermes, INC. | $131.77 | 2022-2023 | Aristada, Lybalvi |
| Lundbeck LLC | $112.63 | 2020-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $105.45 | 2019-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $81.63 | 2021-2024 | Qelbree |
| Jazz Pharmaceuticals INC. | $77.50 | 2019-2022 | |
| Neos Therapeutics, LP | $65.59 | 2020-2021 | |
| Tris Pharma INC | $58.90 | 2023 | Dyanavel Xr |
| Allergan, INC. | $58.88 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $42.47 | 2019 | |
| Corium, LLC | $41.13 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $31.48 | 2022 | |
| Shire North American Group INC | $25.87 | 2019 | |
| Neurocrine Biosciences, INC. | $24.14 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $24.09 | 2019 | |
| Bausch Health US, LLC | $19.87 | 2019 | |
| Axsome Therapeutics, INC. | $17.12 | 2024 | Auvelity |
| Eisai INC. | $16.46 | 2021 | |
| Vanda Pharmaceuticals INC. | $12.37 | 2021 | |
| Adlon Therapeutics L.P. | $11.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joginder Pal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.